Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1990 Nov;86(5):1428–1433. doi: 10.1172/JCI114858

Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.

M R Wessels 1, L C Paoletti 1, D L Kasper 1, J L DiFabio 1, F Michon 1, K Holme 1, H J Jennings 1
PMCID: PMC296886  PMID: 2243123

Abstract

The native capsular polysaccharide of type III group B Streptococcus elicits a specific antibody response in only 60% of nonimmune human subjects. To enhance the immunogenicity of this polysaccharide, we coupled the type III polysaccharide to tetanus toxoid. Prior to coupling, aldehyde groups were introduced on the polysaccharide by controlled periodate oxidation, resulting in the conversion of 25% of the sialic acid residues of the polysaccharide to residues of the 8-carbon analogue of sialic acid, 5-acetamido-3,5-dideoxy-D-galactosyloctulosonic acid. Tetanus toxoid was conjugated to the polysaccharide by reductive amination, via the free aldehyde groups present on the partially oxidized sialic acid residues. Rabbits vaccinated with the conjugate vaccine produced IgG antibodies that reacted with the native type III group B streptococcal polysaccharide (3/3 rabbits), while rabbits immunized with the unconjugated type III polysaccharide failed to respond (0/3 rabbits). Sera from animals receiving conjugate vaccine opsonized type III group B streptococci for phagocytic killing by human peripheral blood leukocytes, and protected mice against lethal challenge with live type III group B streptococci. The results suggest that this method of conjugation to a carrier protein may be a useful strategy to improve the immunogenicity of the type III group B Streptococcus polysaccharide in human subjects.

Full text

PDF
1428

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P., Pichichero M. E., Insel R. A. Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197. J Clin Invest. 1985 Jul;76(1):52–59. doi: 10.1172/JCI111976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baker C. J., Barrett F. F. Group B streptococcal infections in infants. The importance of the various serotypes. JAMA. 1974 Nov 25;230(8):1158–1160. [PubMed] [Google Scholar]
  3. Baker C. J., Edwards M. S., Kasper D. L. Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest. 1978 Apr;61(4):1107–1110. doi: 10.1172/JCI109011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baker C. J., Kasper D. L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976 Apr 1;294(14):753–756. doi: 10.1056/NEJM197604012941404. [DOI] [PubMed] [Google Scholar]
  5. Baker C. J., Kasper D. L. Group B streptococcal vaccines. Rev Infect Dis. 1985 Jul-Aug;7(4):458–467. doi: 10.1093/clinids/7.4.458. [DOI] [PubMed] [Google Scholar]
  6. Baker C. J., Rench M. A., Edwards M. S., Carpenter R. J., Hays B. M., Kasper D. L. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med. 1988 Nov 3;319(18):1180–1185. doi: 10.1056/NEJM198811033191802. [DOI] [PubMed] [Google Scholar]
  7. Baltimore R. S., Kasper D. L., Baker C. J., Goroff D. K. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol. 1977 Feb;118(2):673–678. [PubMed] [Google Scholar]
  8. Boyer K. M., Gadzala C. A., Burd L. I., Fisher D. E., Paton J. B., Gotoff S. P. Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. I. Epidemiologic rationale. J Infect Dis. 1983 Nov;148(5):795–801. doi: 10.1093/infdis/148.5.795. [DOI] [PubMed] [Google Scholar]
  9. Dick W. E., Jr, Beurret M. Glycoconjugates of bacterial carbohydrate antigens. A survey and consideration of design and preparation factors. Contrib Microbiol Immunol. 1989;10:48–114. [PubMed] [Google Scholar]
  10. Dillon H. C., Jr, Khare S., Gray B. M. Group B streptococcal carriage and disease: a 6-year prospective study. J Pediatr. 1987 Jan;110(1):31–36. doi: 10.1016/s0022-3476(87)80283-4. [DOI] [PubMed] [Google Scholar]
  11. Edwards M. S., Fuselier P. A., Rench M. A., Kasper D. L., Baker C. J. Class specificity of naturally acquired and vaccine-induced antibody to type III group B streptococcal capsular polysaccharide: determination with a radioimmunoprecipitin assay. Infect Immun. 1984 May;44(2):257–261. doi: 10.1128/iai.44.2.257-261.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Edwards M. S., Nicholson-Weller A., Baker C. J., Kasper D. L. The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med. 1980 May 1;151(5):1275–1287. doi: 10.1084/jem.151.5.1275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Edwards M. S., Rench M. A., Haffar A. A., Murphy M. A., Desmond M. M., Baker C. J. Long-term sequelae of group B streptococcal meningitis in infants. J Pediatr. 1985 May;106(5):717–722. doi: 10.1016/s0022-3476(85)80342-5. [DOI] [PubMed] [Google Scholar]
  14. Eisenstein T. K., De Cueninck B. J., Resavy D., Shockman G. D., Carey R. B., Swenson R. M. Quantitative determination in human sera of vaccine-induced antibody to type-specific polysaccharides of group B streptococci using an enzyme-linked immunosorbent assay. J Infect Dis. 1983 May;147(5):847–856. doi: 10.1093/infdis/147.5.847. [DOI] [PubMed] [Google Scholar]
  15. Hayden G. F., Sato P. A., Wright P. F., Henderson R. H. Progress in worldwide control and elimination of disease through immunization. J Pediatr. 1989 Apr;114(4 Pt 1):520–527. doi: 10.1016/s0022-3476(89)80687-0. [DOI] [PubMed] [Google Scholar]
  16. Jennings H. J., Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol. 1981 Sep;127(3):1011–1018. [PubMed] [Google Scholar]
  17. Jennings H. J., Lugowski C., Kasper D. L. Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide. Biochemistry. 1981 Aug 4;20(16):4511–4518. doi: 10.1021/bi00519a001. [DOI] [PubMed] [Google Scholar]
  18. Kamerling J. P., Vliegenthart J. F. Identification of O-cetylated N-acylneuraminic acids by mass spectrometry. Carbohydr Res. 1975 May;41:7–17. doi: 10.1016/s0008-6215(00)87002-0. [DOI] [PubMed] [Google Scholar]
  19. Kasper D. L., Baker C. J., Galdes B., Katzenellenbogen E., Jennings H. J. Immunochemical analysis and immunogenicity of the type II group B streptococcal capsular polysaccharide. J Clin Invest. 1983 Jul;72(1):260–269. doi: 10.1172/JCI110965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  21. Lagergard T., Shiloach J., Robbins J. B., Schneerson R. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Infect Immun. 1990 Mar;58(3):687–694. doi: 10.1128/iai.58.3.687-694.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Reuter G., Schauer R., Szeiki C., Kamerling J. P., Vliegenthart J. F. A detailed study of the periodate oxidation of sialic acids in glycoproteins. Glycoconj J. 1989;6(1):35–44. doi: 10.1007/BF01047888. [DOI] [PubMed] [Google Scholar]
  23. Rubens C. E., Wessels M. R., Heggen L. M., Kasper D. L. Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7208–7212. doi: 10.1073/pnas.84.20.7208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. SVENNERHOLM L. Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta. 1957 Jun;24(3):604–611. doi: 10.1016/0006-3002(57)90254-8. [DOI] [PubMed] [Google Scholar]
  25. Schneerson R., Barrera O., Sutton A., Robbins J. B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 1980 Aug 1;152(2):361–376. doi: 10.1084/jem.152.2.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Seppälä I., Mäkelä O. Antigenicity of dextran-protein conjugates in mice. Effect of molecular weight of the carbohydrate and comparison of two modes of coupling. J Immunol. 1989 Aug 15;143(4):1259–1264. [PubMed] [Google Scholar]
  27. Wald E. R., Bergman I., Taylor H. G., Chiponis D., Porter C., Kubek K. Long-term outcome of group B streptococcal meningitis. Pediatrics. 1986 Feb;77(2):217–221. [PubMed] [Google Scholar]
  28. Wessels M. R., Benedí W. J., Jennings H. J., Michon F., DiFabio J. L., Kasper D. L. Isolation and characterization of type IV group B Streptococcus capsular polysaccharide. Infect Immun. 1989 Apr;57(4):1089–1094. doi: 10.1128/iai.57.4.1089-1094.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Wessels M. R., Muñoz A., Kasper D. L. A model of high-affinity antibody binding to type III group B Streptococcus capsular polysaccharide. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9170–9174. doi: 10.1073/pnas.84.24.9170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wessels M. R., Pozsgay V., Kasper D. L., Jennings H. J. Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B Streptococcus. A revised structure for the type III group B streptococcal polysaccharide antigen. J Biol Chem. 1987 Jun 15;262(17):8262–8267. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES